SVB Leerink took its Calithera Biosciences [CALA] rating to the equivalent of Market Perform from Outperform, and the price target to $2, in a research note dated 2021-01-05. Some new analysts also started their coverage, with H.C. Wainwright’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid November. In addition, there was an upgrade from Citigroup on February 16, 2018. The rater changed CALA from “a Neutral” to “a Buy”.
Is Calithera Biosciences Inc. [NASDAQ:CALA] a Good Buy Right Now?
It should be noted that CALA technical indicators for short, intermediate as well as long term progress have placed an overall average of 16% as Sell. The average signal changed from 56% Buy in the last week and compares with 8% Sell in the past month. Data from Calithera Biosciences Inc.’s Trend Spotter indicated that the signals were Bullish. The stock current average is 1.75 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 1.02 million shares while the medium term average advocated for Hold. The average long-term signal stands at 100% Sell and the 100-day average volume stands at 0.77 million shares.
CALA Price Performance
On Wall Street, Calithera Biosciences Inc. [NASDAQ:CALA] finished Monday’s session down -44.60% at $2.72. The stock went up to $3.18 at the same session while its lowest single day price was $2.46. In the last five days, it saw a fall of about -46.67%, Calithera Biosciences Inc. shares dropped by almost -44.60% since the beginning of the year. However, the share price has dropped to as low as -66.75% below its one year high. On 01/04/21, the company shares recorded $3.18, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $2.46. The company’s shares have declined by -46.77% in the past year. The 50-day SMA achieved is $4.52 while the 200-day SMA is $4.86. Volume gained to 16.05 million from 1.26 million in the previous session.
CALA Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 2.39 level, and in case of violation of this particular level, it will cause more drop to 2.07 level. On the upper level, 3.51 is still the key resistance. The stock may increase to the subsequent resistance at 3.11. The Relative Strength Index (RSI) pinned on the 14-day chart is 24.15, implying a oversold technical stance while the MACD stands at -0.78, meaning price will decrease in the next trading period. Percent R indicator moved to 93.02%, implying bearish price movement. Stochastic %K at 9.34% suggest selling the stock.
What is the short interest in Calithera Biosciences Inc.?
Short interest in the Calithera Biosciences Inc. stock has surged, increasing by 0.71 million shares to total 2.02 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 2.73 million, data from Yahoo Finance shows. The decrease of -35.15% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 5.13% of the overall float for the stock.
Calithera Biosciences Inc.’s Biggest Shareholders: Who Owns Calithera Biosciences Inc. [CALA]?
Filings by PRIMECAP Management Co. showed that the firm now holds a total of 10,061,500 shares or roughly 14.26% of the outstanding CALA shares. This means their shares have reduced by -6,300 from the 10,061,500 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Federated Global Investment Manag updated stake is worth $36,594,284. Details in the latest 13F filings reveal that BVF Partners LP disposed off their -35.33% stake valued at $22,515,483 while BlackRock Fund Advisors cut theirs at $21,123,723. During the last quarter, BVF Partners LP liquidated -2,505,000 of its shares in Calithera Biosciences Inc. while BlackRock Fund Advisors sold -7,776 shares. The Point72 Asset Management LP’s holdings currently number 3,727,506 shares at $10138816.32. According to the firm’s last 13F report, The Vanguard Group, Inc. shares in the company at filing stood at 3,368,536 shares, roughly $16,539,512.
CALA Earnings Forecast For The Current Quarter
Calithera Biosciences Inc. [CALA] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $600k and an earnings per share of -$0.32 for Dec 2020.